Wockhardt Slides To Loss Amid US Oncology Push

 
• By Aidan Fry

Investing in its pipeline as it looks to push into the US oncology sector contributed to Wockhardt posting a significant loss despite single-digit sales growth

RandD
Increased research and development investment, coupled with the costs of remediating quality issues at its facilities, contributed to Wockhardt posting a pre-tax loss • Source: Shutterstock

More from Earnings

More from Business